Company Filing History:
7 out of 37 
3 out of 1,343 
Years Active: 2017-2024
Title: Corinne Hanotin: Pioneering Efforts in Antibody Development
Introduction
Corinne Hanotin, an accomplished inventor and researcher based in Paris, France, has made significant contributions to the field of biotechnology, particularly in the development of antibodies for medical treatments. With a total of seven patents to her name, her innovative spirit has led to advancements in treatments for conditions influenced by proprotein convertase subtilisin/kexin type 9 (PCSK9).
Latest Patents
Among her notable patents, Corinne's recent work focuses on human antibodies targeting PCSK9 for therapeutic applications. One of her inventions details methods for treating diseases linked to PCSK9 by administering specific antibodies or antigen-binding fragments. This approach not only involves the antibodies but also the use of inhibitors of HMG-CoA reductase to enhance treatment efficacy. Furthermore, her patented methods outline protocols for testing the effectiveness of these antibodies in various patient groups, including those with heterozygous familial hypercholesterolemia (heFH). By devising targeted therapies using PCSK9-specific antibodies, Corinne is helping to improve treatment outcomes for patients struggling with high cholesterol levels.
Career Highlights
Corinne has collaborated with prominent organizations in the biotechnology sector, including Sanofi Biotechnology and Regeneron Pharmaceuticals, Inc. Her expertise has been instrumental in bringing to fruition groundbreaking therapeutic developments, particularly in the management of cholesterol-related conditions.
Collaborations
Throughout her career, Corinne has worked alongside talented colleagues, including Laurence Bessac and Umesh Chaudhari. Their teamwork has resulted in impactful research, ultimately leading to innovations that are shaping the future of medical treatments.
Conclusion
Corinne Hanotin stands as a remarkable figure in the realm of biotechnology, with her innovative patents and collaborative spirit driving advances in treatment for conditions affected by PCSK9. Her dedication to scientific progress continues to influence the industry and inspire future generations of inventors and researchers.